is compounded semaglutide better than ozempic vs. Digital pharmacy to offer weight-loss
Description
The initial weight loss in the first few weeks is often due to water loss, glycogen (stored carbohydrates), and salt
In 2022, a modified version of the GLP-1/GIP dual agonist, tirzepatide (Zepbound), developed by Eli Lilly induced an average weight loss of 21% in humans with obesity and 15% weight loss in obese patients with diabetes (1)
Clinical implications: Multiple companies are developing muscle-preserving therapies, suggesting this will be an active area of development
Thanks for explaining the fascination with the gelatin trick
